Click here to get full coverage on IDEAYA Biosciences, Inc. $IDYA Shares Sold by Woodline Partners LP - MarketBeat

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Woodline Partners LP  MarketBeat

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Woodline Partners LP - MarketBeat

Click here to get full coverage on Guggenheim Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛

Guggenheim Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $50  富途牛牛

Guggenheim Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛

Click here to get full coverage on Could IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition? - uk.finance.yahoo.com

Could IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition?  uk.finance.yahoo.com

Could IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition? - uk.finance.yahoo.com

Click here to get full coverage on IDEAYA Biosciences Stock Price, Quotes and Forecasts | NASDAQ:IDYA - Benzinga

IDEAYA Biosciences Stock Price, Quotes and Forecasts | NASDAQ:IDYA  Benzinga

IDEAYA Biosciences Stock Price, Quotes and Forecasts | NASDAQ:IDYA - Benzinga

Click here to get full coverage on IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer - PR Newswire

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer  PR Newswire

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer - PR Newswire

Click here to get full coverage on Could IDEAYA (IDYA) Redefine Its Precision Oncology Edge With Encouraging Early Pipeline Results? - simplywall.st

Could IDEAYA (IDYA) Redefine Its Precision Oncology Edge With Encouraging Early Pipeline Results?  simplywall.st

Could IDEAYA (IDYA) Redefine Its Precision Oncology Edge With Encouraging Early Pipeline Results? - simplywall.st

Click here to get full coverage on New Analyst Forecast: $IDYA Given $44.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IDYA Given $44.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IDYA Given $44.0 Price Target - Quiver Quantitative

Click here to get full coverage on IDEAYA Biosciences (IDYA): Valuation Check After Pipeline Progress Sparks Fresh Investor Interest - Sahm

IDEAYA Biosciences (IDYA): Valuation Check After Pipeline Progress Sparks Fresh Investor Interest  Sahm

IDEAYA Biosciences (IDYA): Valuation Check After Pipeline Progress Sparks Fresh Investor Interest - Sahm

Click here to get full coverage on Leerink Partnrs Has Bearish Outlook for IDYA FY2026 Earnings - MarketBeat

Leerink Partnrs Has Bearish Outlook for IDYA FY2026 Earnings  MarketBeat

Leerink Partnrs Has Bearish Outlook for IDYA FY2026 Earnings - MarketBeat

Click here to get full coverage on IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress - PR Newswire

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress  PR Newswire

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors - PR Newswire

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors  PR Newswire

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald  MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat

Click here to get full coverage on IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 6.4% - Should You Sell? - MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 6.4% - Should You Sell?  MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 6.4% - Should You Sell? - MarketBeat

Click here to get full coverage on IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - PR Newswire

Click here to get full coverage on Stephens Reiterates Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Stephens Reiterates Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA)  MarketBeat

Stephens Reiterates Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Click here to get full coverage on IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - PR Newswire

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC  PR Newswire

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - PR Newswire

Click here to get full coverage on Mizuho Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $44.00 - MarketBeat

Mizuho Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $44.00  MarketBeat

Mizuho Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $44.00 - MarketBeat

Click here to get full coverage on IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer  PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% Higher After Analyst Upgrade - MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% Higher After Analyst Upgrade  MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Trading 5.6% Higher After Analyst Upgrade - MarketBeat

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on American Century Companies Inc. Purchases New Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

American Century Companies Inc. Purchases New Stake in IDEAYA Biosciences, Inc. $IDYA  MarketBeat

American Century Companies Inc. Purchases New Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Click here to get full coverage on IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PR Newswire

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors  PR Newswire

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. $IDYA Shares Sold by Trexquant Investment LP - MarketBeat

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Trexquant Investment LP  MarketBeat

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Trexquant Investment LP - MarketBeat

Click here to get full coverage on IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PR Newswire

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer  PR Newswire

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event - PR Newswire

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event  PR Newswire

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Click here to get full coverage on Precision Oncology Updates: IDEAYA Biosciences to Share Multiple Clinical Data at 10-Year Anniversary R&D Day - Stock Titan

Precision Oncology Updates: IDEAYA Biosciences to Share Multiple Clinical Data at 10-Year Anniversary R&D Day  Stock Titan

Precision Oncology Updates: IDEAYA Biosciences to Share Multiple Clinical Data at 10-Year Anniversary R&D Day - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst - Seeking Alpha

IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst  Seeking Alpha

IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst - Seeking Alpha

Click here to get full coverage on IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849 - MSN

IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849  MSN

IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849 - MSN

Click here to get full coverage on IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets  PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer  PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Stock (IDYA) Surging Pre-Market on Promising Trial Data - AskTraders.com

IDEAYA Biosciences Stock (IDYA) Surging Pre-Market on Promising Trial Data  AskTraders.com

IDEAYA Biosciences Stock (IDYA) Surging Pre-Market on Promising Trial Data - AskTraders.com

Click here to get full coverage on 190,421 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Cubist Systematic Strategies LLC - MarketBeat

190,421 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Cubist Systematic Strategies LLC  MarketBeat

190,421 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Cubist Systematic Strategies LLC - MarketBeat

Click here to get full coverage on New Analyst Forecast: $IDYA Given $74.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IDYA Given $74.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IDYA Given $74.0 Price Target - Quiver Quantitative

Click here to get full coverage on Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential  Yahoo Finance

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Yahoo Finance

Click here to get full coverage on Royal Bank Of Canada Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock - MarketBeat

Royal Bank Of Canada Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock  MarketBeat

Royal Bank Of Canada Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock - MarketBeat

Click here to get full coverage on Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN

Ideaya Biosciences gets coverage initiation at Barclays and Citizens  MSN

Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN

Click here to get full coverage on IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha

IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA)  Seeking Alpha

IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha

Click here to get full coverage on LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - 富途牛牛

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58  富途牛牛

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - 富途牛牛

Click here to get full coverage on IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC  PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

Click here to get full coverage on RBC Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA) - The Globe and Mail

RBC Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)  The Globe and Mail

RBC Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA) - The Globe and Mail

Click here to get full coverage on Russell Investments Group Ltd. Acquires 21,535 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Russell Investments Group Ltd. Acquires 21,535 Shares of IDEAYA Biosciences, Inc. $IDYA  MarketBeat

Russell Investments Group Ltd. Acquires 21,535 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Click here to get full coverage on 57% Response Rate: IDEAYA's First-in-Class MAT2A Drug Shows Promise in Hard-to-Treat Bladder Cancer - Stock Titan

57% Response Rate: IDEAYA's First-in-Class MAT2A Drug Shows Promise in Hard-to-Treat Bladder Cancer  Stock Titan

57% Response Rate: IDEAYA's First-in-Class MAT2A Drug Shows Promise in Hard-to-Treat Bladder Cancer - Stock Titan

Click here to get full coverage on IDEAYA Biosciences, Inc. $IDYA Shares Sold by Northern Trust Corp - MarketBeat

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Northern Trust Corp  MarketBeat

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Northern Trust Corp - MarketBeat

Click here to get full coverage on $530 Million Deal: IDEAYA's Breakthrough Eye Cancer Drug Darovasertib Gets Global Partnership with Servier - Stock Titan

$530 Million Deal: IDEAYA's Breakthrough Eye Cancer Drug Darovasertib Gets Global Partnership with Servier  Stock Titan

$530 Million Deal: IDEAYA's Breakthrough Eye Cancer Drug Darovasertib Gets Global Partnership with Servier - Stock Titan

Click here to get full coverage on Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan

Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage  Stock Titan

Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan

Click here to get full coverage on Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $44 - 富途牛牛

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $44  富途牛牛

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $44 - 富途牛牛

Click here to get full coverage on Leerink Partners Maintains IDEAYA Biosciences(IDYA.US) With Hold Rating, Maintains Target Price $30 - 富途牛牛

Leerink Partners Maintains IDEAYA Biosciences(IDYA.US) With Hold Rating, Maintains Target Price $30  富途牛牛

Leerink Partners Maintains IDEAYA Biosciences(IDYA.US) With Hold Rating, Maintains Target Price $30 - 富途牛牛

Click here to get full coverage on Barclays Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Barclays Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA)  MarketBeat

Barclays Begins Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Click here to get full coverage on Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025  Yahoo Finance

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Click here to get full coverage on First-Ever Survival Data: IDEAYA's Breakthrough Treatment for Rare Eye Cancer to be Revealed at Major Congress - Stock Titan

First-Ever Survival Data: IDEAYA's Breakthrough Treatment for Rare Eye Cancer to be Revealed at Major Congress  Stock Titan

First-Ever Survival Data: IDEAYA's Breakthrough Treatment for Rare Eye Cancer to be Revealed at Major Congress - Stock Titan

Click here to get full coverage on Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more - Seeking Alpha

Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more  Seeking Alpha

Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more - Seeking Alpha

Click here to get full coverage on 139,800 Stock Options at $24.93: IDEAYA Biosciences Grants Inducement Awards to Four New Employees - Stock Titan

139,800 Stock Options at $24.93: IDEAYA Biosciences Grants Inducement Awards to Four New Employees  Stock Titan

139,800 Stock Options at $24.93: IDEAYA Biosciences Grants Inducement Awards to Four New Employees - Stock Titan

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says  MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

Click here to get full coverage on Winners Losers: Whats the profit margin of IDYA - Weekly Trend Summary & Breakout Confirmation Alerts - خودرو بانک

Winners Losers: Whats the profit margin of IDYA - Weekly Trend Summary & Breakout Confirmation Alerts  خودرو بانک

Winners Losers: Whats the profit margin of IDYA - Weekly Trend Summary & Breakout Confirmation Alerts - خودرو بانک

Click here to get full coverage on IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up - Time to Buy? - MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up - Time to Buy?  MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up - Time to Buy? - MarketBeat

Click here to get full coverage on IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq

IDEAYA (IDYA) Q2 Net Loss Improves 27%  Nasdaq

IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq

Click here to get full coverage on IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029 - Stock Titan

IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029  Stock Titan

IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029 - Stock Titan

Click here to get full coverage on Is Rising Losses and a Planned Capital Raise Shifting the Investment Case for IDEAYA Biosciences (IDYA)? - simplywall.st

Is Rising Losses and a Planned Capital Raise Shifting the Investment Case for IDEAYA Biosciences (IDYA)?  simplywall.st

Is Rising Losses and a Planned Capital Raise Shifting the Investment Case for IDEAYA Biosciences (IDYA)? - simplywall.st

Click here to get full coverage on IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 5.1% on Analyst Upgrade - MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 5.1% on Analyst Upgrade  MarketBeat

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 5.1% on Analyst Upgrade - MarketBeat

Click here to get full coverage on New Clinical Data Coming: IDEAYA's 3 Cancer Drugs Show Promise in Melanoma and Lung Cancer Trials - Stock Titan

New Clinical Data Coming: IDEAYA's 3 Cancer Drugs Show Promise in Melanoma and Lung Cancer Trials  Stock Titan

New Clinical Data Coming: IDEAYA's 3 Cancer Drugs Show Promise in Melanoma and Lung Cancer Trials - Stock Titan

Click here to get full coverage on IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan

IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference  Stock Titan

IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan

Click here to get full coverage on Trading Recap: What is IDYA s revenue forecast - Trade Entry Summary & Reliable Price Breakout Signals - خودرو بانک

Trading Recap: What is IDYA s revenue forecast - Trade Entry Summary & Reliable Price Breakout Signals  خودرو بانک

Ideaya Biosciences Inc (IDYA)

Price Chart

Key Statistics

Technicals

About IDYA

Latest News

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Woodline Partners LP - MarketBeat

Guggenheim Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛

Could IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition? - uk.finance.yahoo.com

Advanced Charts

Top Gainers

Top Losers